Form 4: Kyverna Therapeutics CFO Ryan Jones Reports Stock and Option Awards

Ryan Alexander Jones, CFO of Kyverna Therapeutics, reports the acquisition of common stock and stock options.

Summary

• On April 11, 2025, Ryan Alexander Jones, the Chief Financial Officer of Kyverna Therapeutics, acquired 12,000 shares of common stock as a restricted stock unit award.
• These shares vest in four equal installments, starting April 11, 2026, and annually thereafter, contingent upon continuous service.
• Jones also acquired options to purchase 74,000 shares of common stock at an exercise price of $2.06 per share.
• These options vest in a combination of quarterly and monthly installments, beginning April 11, 2026, and continuing thereafter, also contingent upon continuous service.
• Following these transactions, Jones directly owns 55,950 shares of common stock and options for 74,000 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating stability and alignment of interests. It's a neutral-positive signal.

Positives

• The granting of stock options and restricted stock units to the CFO aligns his interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules suggest an expectation of continued employment and company growth.

Industry Context

Stock option and restricted stock unit grants are common compensation practices in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used by companies like Amgen, Biogen, and Gilead Sciences.
• The vesting schedules described are typical, aligning with industry norms for incentivizing long-term commitment.
• The size of the grant is likely benchmarked against peer companies of similar market capitalization and stage of development.

Stakeholder Impact

• Shareholders may view the stock and option grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment to the company's future.

Key Dates

Keywords

Form 4, Kyverna Therapeutics, Ryan Jones, CFO, Stock Options, Restricted Stock Units, Beneficial Ownership, KYTX